What We're Reading: Page 315
Industry reads hand-picked by our editors
Dec 08, 2016
-
Bloomberg
Trump team said to consider Thiel associate O'Neill for FDA
-
The Street
Voyager gene therapy shows early, promising motor function improvements for Parkinson's patients
-
Forbes
Gilead's CEO apologetic about Sovaldi's $1,000 per pill price tag
-
Life Sci VC
Hitting the milestones: Update on earning 'biobucks'
Dec 07, 2016
-
The Wall Street Journal
Big pharma, short on blockbusters, outsources the science
-
BloombergGadfly
Juno needs to back a different CAR-T horse
-
Regulatory Focus
Leahy looks to amend ‘Cures’ bill as Senate prepares for passage
-
Forbes
A breast cancer drug that gets in the brain? Cascadian sees a way forward
Dec 06, 2016
-
Reuters
Trump's corporate tax holiday could spur pharma M&A
-
Regulatory Focus
FDA’s Office of New Drugs director to retire
-
The Wall Street Journal
U.S. ‘disappointed’ by Japanese plan to cut drug costs
-
Chicago Tribune
Northwestern, AbbVie team up on cancer research
-
Financial Times
Pharma sector offers rich pickings for management consultants
Previous
